Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion [2]

British Journal of Ophthalmology

Volumn 90, Issue 2, 2006, Pages 243-244

  Lai, Timothy Y Y ^a   Lee, G K Y ^a   Chan, W M ^a   Lam, D S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE MESYLATE; FERRITIN;

ADOLESCENT; BETA THALASSEMIA; BLOOD TRANSFUSION; CASE REPORT; COLOR VISION DEFECT; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; ELECTROOCULOGRAM; FERRITIN BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; IRON OVERLOAD; LETTER; MALE; PRIORITY JOURNAL; RETINOPATHY; TOXIC RETINOPATHY; VISUAL ACUITY;

ADOLESCENT; BETA-THALASSEMIA; DEFEROXAMINE; HUMANS; MALE; RETINAL DISEASES; SIDEROPHORES; VISUAL ACUITY;

EID: 31544462999     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.080119     Document Type: Letter

References (10)

1. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229-30.
2. Haimovici R, D'Amico D, Gragoudas ES, et al. The expanded clinical spectrum of defer examine retinopathy. Ophthalmology 2002;109:164-71.
3. Arden GB, Wonke B, Kennedy C, et al. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984;68:873-7.
4. Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2:181-4.
5. Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986;70:373-81.
6. Bansal V, Elagarbly I, Ghanchi FD, et al. Bull's eye maculopathy with deferoxamine. Eur J Haematol 2003;70:420-1.
7. Gonzales CR, Lin AP, Engstrom RE, et al. Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina 2004;24:464-7.
8. Arora A, Wren S, Gregory Evans K. Desferrioxamine related maculopathy: a case report. Am J Hematol 2004;76:386-8.
9. Lam DSC, Lam TK, Ho PCP, et al. Ocular findings in patients with β-thalassaemia major receiving blood transfusions and desferrioxamine. J Hong Kong Med Assoc 1991;43:133-6.
10. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989;73:403-9.